Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Trial details
- Registry ID
- NCT01436968
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as AdV-tk; CAN-2409
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerNCT01436968 | CADL | Phase 3 | Active not recruiting | 2024-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |